1335097-33-0

Upstream product

• 79271-56-0 triethylsilyl trifluoromethyl sulfonate 
• 1335097-32-9 (20S,22R)-des-A,B-22-methyl-25-[(triethylsilyl)oxy]cholestan-8-one 
• 213250-64-7 [2-[(3'R,5'R)-3',5'-bis[(tert-butyldimethylsilyl)oxy]-4'-methylenecyclohexylidene]ethyl]diphenylphosphine oxide 
• 1335097-30-7 (8S,20S)-des-A,B-22-methyl-8β,25-bis[(triethylsilyl)oxy]cholestane 
• 305371-75-9 (8S,20S,22R)-des-A,B-22-methylcholestane-8β,25-diol 
• 305371-76-0 (20S,22R)-De-A,B-25-hydroxy-22-methylcholestan-8-one 

Downstream Products

• 1335097-44-3 (20S,22R)-2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3 

Relevant academic research and scientific papers

A 20 S combined with a 22 r configuration markedly increases both in vivo and in vitro biological activity of 1α,25-Dihydroxy-22-methyl-2-methylene- 19-norvitamin D3

Six new analogues of 1α25-dihydroxy-19-norvitamin D3 (3a-4b, 5, and 6) were prepared by a convergent synthesis applying the Wittig-Horner reaction as a key step. The influence of methyl groups at C-22 on their biological activity was examined.

DIASTEREOMERS OF 2-METHYLENE-19-NOR-22-METHYL-1ALPHA,25-DIHYDROXYVITAMIN D3

Compounds of formula I are provided where X1, X2, and X3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a vari